MiR-1207-5p targets PYCR1 to inhibit the progression of prostate cancer

• DOI: 10.1016/j.bbrc.2021.08.037
• Publication Date: 2021-08-15T05:53:08Z
• Authors: Haixia Xu; Yan He; Lin Lin; Meixiang Li; Zeqiang Zhou; Yi Yang
• Keywords: Male; 0303 health sciences; Prostatic Neoplasms; Apoptosis; 3. Good health; MicroRNAs; delta-1-Pyrroline-5-Carboxylate Reductase; 03 medical and health sciences; Cell Movement; Cell Line, Tumor; Disease Progression; Humans; Pyrroline Carboxylate Reductases; Cell Proliferation

Prostate cancer, the most common non-cutaneous male cancer, is a public health problem with a third prevalence worldwide. PYCR1 and miR-1207-5p dysregulations were found in cancer progression. Our study aims to reveal the biological role of miR-1207-5p-PYCR1 axis in prostate cancer progression. First, we investigated the expression of miR-1207-5p in prostate cancer tissues and cell lines by RT-qPCR. Next, we confirmed miR-1207-5p targeting PYCR1 by luciferase assay. CCK-8 assay, BrdU assay, flow cytometry, and tanswell assay were applied for examining cell proliferation, apoptosis, and invasion in prostate cancer cells, respectively. In the present study, decreased miR-1207-5p expression was obviously observed in prostate cancer tissues and cells. Upregulation of miR-1207-5p hampered cellular proliferation and invasion, while enhanced cellular apoptosis. In addition, upregulation of PYCR1 elevated cell proliferation and invasion, but repressed apoptosis of prostate cancer cells. Moreover, miR-1207-5p inhibited the expression of PYCR1 to repress prostate cancer tumorigenesis. MiR-1207-5p inhibited the expression of PYCR1 to repress the progression of prostate cancer by inhibiting cell growth and elevating cell apoptosis. Overall, our study clarifies the biological role of miR-1207-5p-PYCR1 axis in prostate cancer progression, which might be effective biomarkers for clinical treatment of prostate cancer.